Keith A. Meister bought $13M of WGS
director, owner at GeneDx Holdings Corp.. 169,521 shares at an average of $79.40, traded Mar 3, 2026, filed Mar 5, 2026.
Score components
- +15RoleDirector
- +25Trade size$13.5M at market
- +3Relative to holdingsHoldings up 6%
- +8Price context54% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-094527, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +19,686 | $70.34 | $1.4M | 3,078,315 | Mar 5, 2026 |
| Mar 3, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +8,439 | $71.48 | $603k | 3,086,754 | Mar 5, 2026 |
| Mar 3, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +200 | $72.00 | $14k | 3,086,954 | Mar 5, 2026 |
| Mar 3, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +921 | $75.66 | $70k | 3,087,875 | Mar 5, 2026 |
| Mar 3, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +249 | $75.99 | $19k | 3,088,124 | Mar 5, 2026 |
| Mar 5, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +304 | $77.96 | $24k | 3,088,428 | Mar 5, 2026 |
| Mar 5, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +1,971 | $78.91 | $156k | 3,090,399 | Mar 5, 2026 |
| Mar 5, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +47,623 | $80.55 | $3.8M | 3,138,022 | Mar 5, 2026 |
| Mar 5, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +60,892 | $81.37 | $5.0M | 3,198,914 | Mar 5, 2026 |
| Mar 5, 2026 | POpen-market purchase Class A Common Stockindirect: See footnotes | +29,236 | $82.06 | $2.4M | 3,228,150 | Mar 5, 2026 |
Related signals
Other insiders at GeneDx Holdings Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $364k 3,728 shares | -8% | |
| 43Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.0M 10,501 shares | -8% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $108k 1,285 shares | -3% | |
| 32Weak | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $311k 3,692 shares | -3% | |
| 20Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $31k 372 shares | -1% | |
| 39Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $557k 8,818 shares | -20% | |
| 53Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $3.0M 46,933 shares | -34% | |
| 37Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $438k 5,706 shares | -17% | |
| 48Moderate | GeneDx Holdings Corp. | Katherine Stueland CHIEF EXECUTIVE OFFICER | $1.3M 17,179 shares | -23% | |
| 25Weak | GeneDx Holdings Corp. | Kevin Feeley CHIEF FINANCIAL OFFICER | $111k 1,280 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.